Editor's key points † Etomidate causes suppression of adrenal function but is still used for patients undergoing cardiac surgery. † Its effects on vasopressor use after cardiac surgery are not known. † In this study, etomidate caused relative adrenal insufficiency in the first 24 h after operation. † There were no differences in norepinephrine requirements; the effects on outcome in these patients remain unclear.
However, confounding factors often prevent a clear interpretation of these studies, especially post hoc or subgroup analyses, and the use of etomidate in more severely ill patients. 9 A recent study conducted in 655 patients requiring emergency intubation reported a lack of detrimental effect of etomidate compared with ketamine. 10 Cardiac surgery constitutes a significant stimulus for the endogenous release of stress hormones.
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Although adrenal insufficiency induced by etomidate has been demonstrated in several studies of perioperative patients, 12 -17 surprisingly none measured the haemodynamic consequences of this inhibition. Etomidate is commonly used for induction of anaesthesia before cardiac surgery owing to its relative cardiovascular stability. 18 19 Postoperative haemodynamic alterations are common after cardiac surgery, thus a functioning adrenal axis is essential. A decrease in cortisol synthesis related to etomidate administration may dramatically affect the haemodynamic status of such patients, particularly in view of the systemic inflammatory state triggered by cardiopulmonary bypass (CPB). 20 21 The aim of this study was to compare norepinephrine usage over the first 48 h after cardiac surgery with CPB after a single dose of either etomidate or propofol administered for induction of anaesthesia.
Adult patients undergoing coronary artery bypass grafting (CABG), valve replacement, or combined procedure, under CPB, were included. Only patients operated upon during the morning were considered due to the circadian rhythm of cortisol secretion. Exclusion criteria were pregnancy, age below 18 yr, known adrenal insufficiency, administration of any corticosteroid within the last 3 months, non-interruption of angiotensin-converting enzyme inhibitor or angiotensin II receptor antagonist treatment the day before surgery, an emergency procedure, current infection, aortic stenosis, or an acute coronary syndrome (ACS) during 3 weeks before surgery.
Randomization was performed centrally on the morning of surgery by the hospital research department with allocation concealed in permuted blocks of variable size (2, 4, and 6 The bypass pump was primed with 500 ml of hydroxyethyl starch 130/0.4 and 1000 ml of normal saline solution. Unfractioned heparin was administered before CPB initiation (300 IU kg 21 ) to obtain an activated clotting time of .400 s.
Surgery was performed under mild hypothermia (358C) with cardioplegia achieved using cold St Thomas' hospital solution. Antifibrinolysis was initially delivered using aprotinin, stratified to haemorrhagic risk, but the protocol was later amended to tranexamic acid due to prohibition on aprotinin use. 22 At the end of the operation, patients remained sedated and with mechanical ventilation, and were immediately transferred to the postoperative intensive care unit (ICU). Propofol was initiated at 2 mg kg 21 h 21 and titrated to reach level 3 on the Riker Sedation-Agitation Scale. Multimodal analgesia was standardized using tramadol, paracetamol, and ketoprofen. The goal-directed protocol for fluid and vasopressor drug administration used during surgery was continued after operation. Delta pulse pressure (delta PP) was measured in the first postoperative hours when patients were sedated with no spontaneous respiration and only for those with sinusal cardiac rhythm. The patient was considered hypovolaemic if delta PP ,13%. Patients were transfused if their haemoglobin level decreased below 10 g dl 21 . Sedation was discontinued when patients were normothermic (.36.58C) and haemodynamically stable with blood loss through mediastinal drains ,50 ml h 21 and a urine output exceeding 0.5 ml kg 21 . There was no weaning protocol in the unit, but patients were then rapidly set to pressure support ventilation to allow spontaneous breathing. Extubation criteria were checked when the patient was calm, conscious, oriented, and pain-free. were assessed 6 h after ICU admission. A serious adverse event (SAE) was defined as any life-threatening event causing prolongation of hospital stay or resulting in permanent disability or death. The primary study endpoint was comparison of norepinephrine usage between the two groups. A priori secondary endpoints included time to vasopressor drug withdrawal, inotrope drug use, and adrenocortical function measured at 12, 24, and 48 h after etomidate administration.
An independent data safety and monitoring committee reviewed study results and adverse events, and the incidence of ACS, ruling on study continuation after each 30 patients enrolled.
Statistical analysis
In a pilot study of 27 patients receiving propofol, the mean (SD) norepinephrine use was 0.20 (0.15) mg kg 21 min 21 over the first 48 h after operation. Ninety-four patients were thus needed to detect a 50% increase in norepinephrine requirements between the two groups with a two-sided a-value of ,5% and a power of 90% (b-value of 10%). Descriptive statistics were expressed as frequencies and percentages for categorical variables, and as means for continuous variables. Norepinephrine usage was analysed with an area under the curve (AUC) analysis for each patient. AUCs were compared between the groups using a t-test. The duration of catecholamine weaning was analysed by the Kaplan-Meier curves and log-rank test. Comparisons between the two groups used Student's t-test for quantitative variables, the x 2 test for qualitative variables, and a one-way analysis of variance followed by a post hoc Dunnett's test as the multiple comparison method (for cortisol and troponin measurements). Statistical significance was regarded as P,0.05. Statistical analysis was performed using SAS version 9 (SAS Institute Inc., Cary, NC, USA). Patients' data were analysed on an intention-to-treat basis.
Results
During the study period, 51 and 49 patients were enrolled in the etomidate and control groups, respectively. CABG was performed using the octopus stabilizer without CPB for three patients (one etomidate, two controls). In one etomidate group patient, CABG proved impossible due to coronary artery calcification. Patient characteristics were well balanced between the two groups (Table 1) . Valve replacement, CABG, and combined procedures represented 50%, 40%, and 10% of the cases in each group, respectively. No difference was seen in the duration of CPB or aortic clamping between groups, and aprotinin and tranexamic acid doses were similar (Table 2) . Aprotinin was administered in 63% and 53% of the patients in, respectively, the etomidate and control groups (P¼0.33). Tranexamic acid was administrated in 37% and 47% of the patients in, respectively, the etomidate and control groups (P¼0.72). Intra-and postoperative fluid requirements and blood transfusions were also similar between the groups (Tables 2 and 3 ). The mean (SD) duration of sedation in the ICU was 8 (4) and 9 (6) h in the etomidate and control groups, respectively (P¼0.83).
Arterial pressure was not significantly different between the groups during the postoperative period (data not (Table 4) . According to our definition, the incidence of RAI occurred more frequently in the etomidate group at 12 and 24 h, but this difference was no longer significant at 48 h (Fig. 2) . Approximately 40% and 25% of the control group patients were corticotrophin non-responders at 12 and 24 h after propofol administration, respectively. No significant differences were seen in the biological markers of inflammation sampled at 6 h post-ICU admission: IL-6 levels were 189 (168) (Table 3) . According to our definition, 4 (8%) etomidate group patients and 6 (12%) control group patients met the criteria for ACS (P¼0.27). The incidence of SAEs was significantly higher with 9 (18%) in the control group and 3 (6%) in the etomidate group (P¼0.04) ( Table 5 ). Three patients developed cardiovascular complications, all in the control group: one died in refractory cardiogenic shock while two suffered ventricular arrhythmia with cardiogenic shock and cerebral stroke. Five patients suffered from postoperative complications (mediastinitis, acute mediastinal bleeding). Outcome (hospital length of stay and hospital mortality) did not differ between groups (Table 3) . 
Discussion
In this study, we found that a single bolus of etomidate at induction of anaesthesia in patients undergoing elective cardiac surgery led to RAI for ,48 h, but this was not associated with an increase in requirements for vasopressor drugs. Several factors can explain this lack of difference. First, the study may be underpowered as the sample size was calculated using preliminary data showing higher norepinephrine use with propofol. However, post hoc power analysis revealed a very acceptable rate of 86%, thus excluding any major type II statistical error. The absence of haemodynamic consequences associated with etomidate may be related to the population included in our study, as reflected by their preoperative ejection fraction values and low EuroSCORE. Propofol constitutes probably the only alternative i.v. anaesthetic induction agent in this population, but its use in haemodynamically unstable patients or in those with severely restricted myocardial function would have been problematic. The level of proinflammatory cytokines was particularly low in both groups. The intensity of inflammation is associated with multi-organ failure after cardiac surgery. 24 25 The effect of etomidate may have been different if patients had risk factors for a subsequent systemic inflammatory response, namely CPB duration .97 min or a preoperative ejection fraction ,40%. 25 However, despite these limitations, a 100% rate of RAI seen at 12 h in the etomidate group would have likely produced at least a trend towards an increase in norepinephrine requirements, had etomidateinduced inhibition of cortisol synthesis led to significant haemodynamic alterations. The high frequency of RAI in the control group at 12 and 24 h after propofol administration could have narrowed the difference between the two study groups. Recently, a study reported an RAI incidence of 57% in 120 etomidate-free patients undergoing elective cardiac surgery with CPB. 26 The aetiology of RAI in the critically ill is not clearly established, though stress induced by surgery and inflammation are two well-recognized risk factors. 14 27 28 Although the incidence of RAI is well documented, the duration of adrenal inhibition and its haemodynamic consequences remain unclear, particularly in surgical patients. The incidence of RAI after etomidate administration was not statistically different from control patients at 48 h. This supports the recent finding reported in 40 patients requiring emergency intubation, of whom 32 (80%) fulfilled RAI criteria at 12 h, but only 9% and 7% at 48 and 72 h, respectively. 29 However, the response of the HPA axis to corticotrophin is probably blunter for a longer period as we found that cortisol inhibition remained significantly greater at 48 h. The inhibition of 11 b-hydroxylase by etomidate is probably incomplete as blood cortisol levels remained relatively high. Some authors suggest that the decrease in plasma cortisol concentrations was compensated by an increase in ACTH secretion. 13 There have been few previously published studies regarding the postoperative haemodynamic consequences of adrenal insufficiency. In colorectal surgery, catecholamine requirements were not significantly different between patients receiving hydrocortison or placebo supplementation after a single dose of etomidate; however, crystalloid administration was considerably higher in the placebo group. 17 The anti-inflammatory effects of increasing doses of hydrocortisone in patients receiving etomidate for induction of anaesthesia in cardiac surgery have been reported. 30 No significant differences were seen with respect to vasopressor requirements, duration of postoperative ventilation, and hospital stay between a control group receiving thiopental and an etomidate group not receiving hydrocortisone supplementation. In a recent retrospective study, 63 patients presenting acute circulatory failure requiring norepinephrine after cardiac surgery and etomidate administration have been studied. 15 All patients received hydrocortisone supplementation. The authors have compared patients with and without adrenal insufficiency and did not find any increase in norepinephrine use, but this study had multiple methodological limitations. The controversy surrounding the haemodynamic consequences of etomidate-related adrenal insufficiency comes predominantly from either post hoc or retrospective subgroup analysis of trials in patients with septic shock 6 7 or those requiring emergency intubation in Emergency Departments. 31 32 A recent prospective randomized study compared etomidate with ketamine in 655 patients requiring emergency tracheal intubation. 10 The authors concluded that a single bolus dose of etomidate was not associated with a significant increase in morbidity as evaluated by the maximum SOFA score over the following 3 days, even for the haemodynamic component of the score.
In conclusion, a single injection of etomidate was not associated with increased use of vasopressor agents in an elective cardiac surgical population requiring CPB. However, due to its significant inhibition of the adrenal axis, etomidate should be used with caution in high-risk cardiac surgical patients until studies determine its safety.
